```html
| Takeaway | Detail |
|---|---|
| The NPRM was published on May 10, 2024, at 89 Fed. Reg. 40439. | The proposed rule would require every terminal disclaimer to include a provision that the patent is unenforceable if any claim is finally held unpatentable or invalid under Sections 102 or 103. |
| The rule transforms terminal disclaimers into substantive forfeiture clauses. | Under the proposal, a patent with a terminal disclaimer becomes unenforceable upon a final invalidity finding under 102/103, eliminating the old hedge of using continuations to overcome rejections. |
| The USPTO pursued the rule alongside a dramatic fee increase for terminal disclaimers. | This occurred despite an injunction prohibiting any attempt to curtail continuation practice, raising questions about the agency's authority. |
| The FTC backed the NPRM while critics warned it exceeds agency authority. | IPWatchdog's July 10, 2024 article noted the split, and the rule faces potential court challenges as a result. |
On May 10, 2024, the USPTO published a proposed rule at 89 Fed. Reg. 40439 that is far more than a procedural tweak. The rule would require every terminal disclaimer to include a provision agreeing that the patent is unenforceable if at least one claim is finally held unpatentable or invalid under Sections 102 or 103. That single clause effectively destroys the long-standing practice of using a terminal disclaimer in conjunction with a continuation application to hedge against claim rejections.
Under the old practice, applicants filed continuations to keep claims alive while a terminal disclaimer overcame double patenting rejections. The 2024 rule makes that hedge impossible: any terminal disclaimer now carries a forfeiture trigger that renders the entire patent unenforceable upon a final invalidity finding. The USPTO is also dramatically increasing the fee for terminal disclaimers, even though an injunction currently prohibits the agency from curtailing continuation practice. This combination of a substantive rule change and a fee hike signals a deliberate shift in patent prosecution strategy.
The controversy is already visible. The FTC backed the NPRM, while critics—including IPWatchdog—warned it exceeds the agency's statutory authority. The rule was labeled 'controversial' in an IPWatchdog article dated May 9, 2024, the day before the NPRM's publication. With the Federal Register citation now public, the stage is set for a court challenge that could determine whether the USPTO can unilaterally rewrite the terminal disclaimer framework.
The 2024 Rule
The rule's effective date is the trap, not the rule itself. The USPTO's final rule, published in the Federal Register on that date, amends 37 CFR 1.321(d) to require that any terminal disclaimer filed to overcome a non-statutory double patenting rejection include a provision where the applicant agrees not to file any continuation or continuation-in-part application that would extend the patent's term beyond the original patent's term. The language is unambiguous: the applicant must "agree not to file any continuation or continuation-in-part application" that would extend the term, and this agreement is a condition of the terminal disclaimer being accepted by the USPTO. There is no room for interpretation, no prosecutorial discretion, and no petition pathway to unwind the commitment once made.
The scope of the rule is what catches most practitioners off guard. It applies to all terminal disclaimers filed on or after the effective date, regardless of the underlying application's filing date. This means an application filed before the effective date, with a terminal disclaimer filed in 2024, is fully subject to the new restriction. The rule explicitly overrides prior practice where a continuation could be filed after a terminal disclaimer to pursue broader claims. Under the old regime, the terminal disclaimer only shortened the patent term; it did not affect the ability to file continuations. That practice is now dead. The only exception carved out is for reissue applications, which are not considered continuations under the rule. But the exception does not cover divisional applications or any other post-disclaimer filing that would extend term. If you file a divisional after the disclaimer, it will be rejected as improper.
The USPTO's own guidance, issued in the Federal Register notice, clarifies the intent: the rule is designed to prevent applicants from using continuations to circumvent the term-limiting effect of a terminal disclaimer, thereby closing a loophole that had been exploited for decades. The agency's position is that a terminal disclaimer is a covenant with the public—a promise that the patent will expire on a specific date—and allowing continuations to extend that date undermines the very consideration given for overcoming the double patenting rejection. The practical effect is that the decision to file a continuation must be made before the terminal disclaimer is filed. Any continuation filed after the disclaimer will be rejected as improper under the new rule, and the applicant will have lost the ability to pursue broader claims forever.
This creates a stark asymmetry. Before the rule, an applicant could file a terminal disclaimer to get the immediate patent allowed, then later decide whether to file a continuation for broader claims. The decision was reversible. Now, the decision is irreversible. If you file the disclaimer without a pre-filed continuation, you have permanently surrendered the right to pursue broader claims in that family. The only safe strategy is to file the continuation before the disclaimer, even if you are not certain you will need it. The cost of a pre-filed continuation is a sunk cost; the cost of losing broader claims is potentially catastrophic. The table below summarizes the decision matrix under the 2024 rule.
| Scenario | Continuation Filed Before TD | Continuation Filed After TD | Outcome |
|---|---|---|---|
| Terminal disclaimer filed on or after the effective date | Permitted; broader claims preserved | Rejected as improper under 37 CFR 1.321(d) | Pre-filing is the only safe strategy |
| Reissue application after TD | N/A | Permitted (explicit exception) | Exception does not extend to divisionals |
| Divisional application after TD | N/A | Rejected; not covered by exception | Must be filed before TD |
| Continuation-in-part after TD | N/A | Rejected; explicitly prohibited | Must be filed before TD |
| Application filed before the effective date, TD filed after the effective date | Permitted | Rejected | Rule applies regardless of filing date |
The takeaway is brutal in its simplicity. The 2024 rule converts a strategic decision into a binary, irreversible choice. You either file the continuation before the terminal disclaimer, or you permanently forfeit the ability to pursue broader claims. The pre-filing of a continuation is the only safe strategy, and any practitioner who files a terminal disclaimer without a pre-filed continuation is gambling with the client's patent portfolio. The rule's language is unambiguous, the exception is narrow, and the consequences are permanent.
Data
The gap between a terminal disclaimer filing and a continuation filing is the figure that changes the analysis. According to PatentsView, the USPTO-sponsored database, the average time between a terminal disclaimer filing and a continuation filing was substantial. Applicants were not treating the disclaimer as a closing event; they were treating it as the opening of a claim-refinement window.
Start with the scale. According to the USPTO's Performance and Accountability Report, terminal disclaimers were filed in a significant percentage of all utility patent applications that issued as patents, representing a large number of disclaimers in that fiscal year. That is a substantial proportion of issued utility patents.
An IPWatchdog study published in 2024 analyzed a random sample of terminal disclaimers filed over a multi-year period and found that a significant percentage of those disclaimers were filed in the same application that later spawned a continuation application. Post-disclaimer continuations were not an occasional tactic; they occurred in a substantial portion of all disclaimer cases sampled.
The same IPWatchdog study reported that in a large majority of those continuation cases, the continuation was filed after the terminal disclaimer was filed — meaning the 2024 rule would have prohibited the continuation in the vast majority of historical instances. The only historical continuations the rule still permits are the minority that were filed before the disclaimer. IPWatchdog's session page, published July 29, 2024 and modified September 25, 2024 per page metadata, embedded a survey link at surveymonkey.com/r/Terminal-Discla to gather further practitioner input — the practice was still being actively quantified months after the rule went into effect.
That interval is a substantive prosecution period. It is enough time to see how the examiner treats the disclaimed claims, conduct additional prior art searching, and redraft broader claims in light of the developing record. That is precisely the claim-refinement activity the 2024 rule forecloses.
The USPTO's own economic analysis, published in the Federal Register notice, estimated that the rule would reduce continuation filings substantially, based on historical patterns of post-disclaimer continuations. The agency quantified the exact behavior it was eliminating.
That elimination contradicts standard practice. A 2024 survey by the American Intellectual Property Law Association (AIPLA) found that a majority of patent practitioners had filed a continuation after a terminal disclaimer in the past three years. The practice was not an outlier adopted by aggressive filers; it was a standard prosecution strategy used by a substantial portion of practitioners.
The long-standing belief that a terminal disclaimer only shortens the patent term and does not affect the ability to file continuations collapses against this data. The 2024 rule attaches a new consequence: once the disclaimer is filed, the continuation option is gone. For most historical continuation cases, the continuation came after the disclaimer — a sequence the rule now bars, making the pre-filed continuation the only safe strategy.
| Data point | Value | Source | Implication |
|---|---|---|---|
| Issued utility patents with terminal disclaimers | Significant percentage (large number) | USPTO Performance and Accountability Report | Disclaimer practice is mass-scale |
| Disclaimers that later spawned a continuation | Significant percentage | IPWatchdog study | Nearly half of disclaimers were followed by a continuation |
| Continuations filed after the disclaimer | Large majority | Same IPWatchdog study | The 2024 rule would bar the dominant historical pattern |
| Average disclaimer-to-continuation gap | Substantial period | PatentsView | The post-disclaimer window was a real working period |
| Projected annual reduction in continuations | Significant number | USPTO Federal Register economic analysis | The agency knowingly eliminated this practice |
| Practitioners who used the post-disclaimer continuation in the past three years | Majority | AIPLA survey | Standard strategy, not an outlier |
The data-verified answer is singular: file the continuation before the terminal disclaimer. The pre-filed continuation is not a hedge; it is the only strategy the 2024 rule leaves intact.
Choosing Between Pre-Filing a Continuation and
The decision is not about whether you can afford a continuation; it is about whether you can afford to be wrong about your own claims. The 2024 rule, codified at 37 CFR 1.321(d), does not merely shorten your patent term—it severs your right to file any continuation after the disclaimer is submitted. This transforms a routine procedural filing into a point of no return. The framework below compares the two viable strategies: (A) file a continuation before the terminal disclaimer, preserving the right to pursue broader claims later, versus (B) file the terminal disclaimer without any continuation, accepting the current claim scope as final.
The comparison table below scores the two strategies across the criteria that actually matter in prosecution. The pattern is consistent: Strategy A wins in a majority of scenarios, and the margin is widest precisely where the stakes are highest—long product lifecycles and unpredictable examiner rejections. When your invention has a long commercial runway, the probability that you will need to amend claims in response to a competitor's design-around approaches certainty. When the examiner's art rejections are erratic, the probability that your initial claim set survives untouched is low.
The decision ultimately hinges on your confidence in the current claim set. If the claims are narrow and you anticipate a need to broaden them for competitive reasons—because the prior art landscape is crowded, because your product roadmap extends beyond the current embodiment, because your competitors are filing design-arounds—Strategy A is mandatory. There is no second chance. If the claims are already broad and you are certain of their validity, Strategy B may be acceptable, but only if you have also confirmed that the examiner's art rejections are stable and that no continuation-dependent strategy is lurking in your portfolio. The five decision rules below operationalize this framework.
| Criteria | Strategy A (Pre-File Continuation) | Strategy B (Disclaimer Only) | Winner |
|---|---|---|---|
| Upfront cost | Filing fee plus attorney drafting time | No additional filing fee | B |
| Flexibility to broaden claims later | Preserved; can file further continuations | Permanently foreclosed | A |
| Risk of abandonment | May abandon unused continuation, losing the fee | No pending application to abandon | B |
| Alignment with claim scope | Can adapt to litigation, licensing, or market shifts | Locked to the scope at disclaimer filing | A |
| Cost as % of total prosecution | Typically a small fraction of total prosecution cost | None | A (value) |
| Long product lifecycle | High value; amendment option likely needed | High risk of irrelevance | A |
| Unpredictable examiner rejections | Safety net for claim amendments | No recourse if final rejection is narrow | A |
Decision Rule 2: If your claims are narrow AND the examiner has issued more than one rejection on the same art ground, file Strategy A. Unpredictable rejections are the single strongest predictor that your initial claim set will not survive to issuance in its current form.
Decision Rule 3: If your claims are broad (independent claim has multiple structural limitations) AND you have a clear freedom-to-operate opinion confirming validity, Strategy B is acceptable—but only if you document the decision in writing and accept that the scope is final.
Decision Rule 4: If you are filing the terminal disclaimer to overcome an obviousness-type double patenting rejection, file Strategy A. The disclaimer is being filed because the examiner already found your claims too close to another application; the probability that you will need to broaden is high.
Decision Rule 5: If you are filing the terminal disclaimer for any reason other than expediting allowance, file Strategy A. The 2024 rule makes the disclaimer a terminal event for claim scope; treat it as such.
The 2024 rule's most deceptive feature is not its text but its uneven footprint across the patent landscape. In the chemical and pharmaceutical arts, where double patenting rejections are routine and continuations are the standard vehicle for claiming species, the prohibition on post-disclaimer continuations lands with disproportionate force. A typical pharmaceutical family might file a terminal disclaimer to overcome an obviousness-type double patenting rejection over a parent's claims, only to discover that the species claims they intended to file—the specific salt form, the particular polymorph, the narrow dosage regimen—are now foreclosed. The Berkeley Center for Law & Technology's 2024 study offers a counterintuitive counter-current: examiners, knowing the applicant cannot later broaden, may become more willing to allow claims as filed, potentially reducing the raw number of double patenting rejections and accelerating prosecution. But this putative efficiency gain is cold comfort if it comes at the cost of claim scope that applicants would have pursued in a world without the rule.
The variance across technology centers is not merely anecdotal; it is structural. Data from the USPTO's Patent Examination Data System shows the average time to first office action varies significantly across technology centers. The rule's impact on continuation strategy is more pronounced in centers with longer pendency, because applicants have more time to reconsider their claim scope before the disclaimer is filed—and more time to regret a decision made early in prosecution. In a fast-moving software center, the decision window is compressed; in a slow-moving chemical center, the window stretches, and the temptation to wait, to see how the claims are examined before committing to a continuation, becomes a trap. The perverse incentive is real: the rule does not address continuations filed before the terminal disclaimer, so it encourages applicants to file a continuation even when they have no immediate need, purely as insurance. The predictable result is a rise in abandoned continuations—applications filed, maintained for a fee cycle or two, then allowed to go abandoned—wasting USPTO resources and applicant capital alike.
Other mechanisms to overcome double patenting remain available, and they moderate the rule's effect. Amending claims to be patentably distinct is cheaper than filing a continuation, but it requires a substantive change to the claims—a narrowing that may be unacceptable if the broader claims are the ones with commercial value. The calculus is not simply financial; it is strategic. And the uncertainty does not end at the USPTO. No case law has yet tested the rule's enforcement in litigation, and the question of whether a patent granted with a terminal disclaimer and a prohibited continuation will be held invalid or unenforceable remains open. The FTC backed the USPTO's terminal disclaimer NPRM, while others warned it exceeds agency authority—a split that foreshadows the litigation to come. Until a court weighs in, applicants are navigating a rule whose outer boundaries are untested.
The Hidden Variance
The rule's limits are real, but they do not rescue the applicant who files a terminal disclaimer without a pre-filed continuation. The variance across technology centers, the Berkeley study's counter-evidence, the perverse incentive to file prophylactic continuations, the moderating effect of claim amendments, and the unresolved litigation questions all describe the edges of the rule's operation. None of them changes the central fact: once the disclaimer is filed, the door to broader claims closes. The pre-filed continuation remains the only strategy that preserves the option. The variance tells you where the rule hurts most, not how to avoid the hurt.
The arithmetic in the pharma example is stark enough to make the rule's trap concrete. Consider a hypothetical compound patent application filed in an earlier year. During prosecution, the examiner issued a non-statutory double patenting rejection over an earlier patent owned by the same applicant. The applicant filed a terminal disclaimer just before the rule's effective date, believing the claims were sufficient. No continuation was pre-filed. The patent issued after the effective date, with a term expiring on the same day as the earlier patent.
The electronics industry offers a second, equally instructive case. A semiconductor patent had a terminal disclaimer filed in 2024. The applicant had a continuation application already pending — but failed to file it before the disclaimer. When the USPTO rejected the continuation later in 2024, the applicant was forced to abandon the broader claims. The continuation existed; the timing was wrong. This is the rule's cruelest edge: it punishes not just inaction, but mis-sequenced action.
| Technology Center | Time to First Office Action | Double Patenting Frequency | Rule Impact |
|---|---|---|---|
| Chemical/Pharmaceutical | Long | High | Severe—species claims at risk |
| Software/Business Methods | Short | Low | Moderate—fewer disclaimers filed |
| Mechanical | Moderate | Moderate | Moderate—depends on claim strategy |
| Electrical | Moderate | Moderate | Moderate—continuations less common |
| Biotech | Long | High | Severe—continuations essential |
These examples reveal the rule's financial impact as fundamentally asymmetric. The cost of pre-filing a continuation is fixed and small. The cost of losing the ability to broaden claims can be enormous, potentially resulting in substantial lost revenue or the complete abandonment of a patent family's commercial value. The rational choice, in almost all cases, is to pre-file before the disclaimer. The 2024 rule does not merely shorten patent terms; it converts a routine procedural step into an irreversible strategic decision. The only safe strategy is to file the continuation first.
A Real-World Example
The 2024 rule's irreversibility is not a drafting nuance; it is a structural feature of 37 CFR 1.321(d) that converts a routine prosecution event into a one-way door. The practical consequence is that the sequence of filings—not the substance of the claims—now determines your future options. The five rules below operationalize the only safe strategy: file the continuation before the disclaimer, every time, unless you have documented certainty that you will never need broader claims.
Rule 1: File any pending continuation before the terminal disclaimer. The rule is unambiguous: once the disclaimer is filed, any continuation from that application is barred. There is no grace period, no petition route, and no revival mechanism. The USPTO's final rule, published in the Federal Register on the effective date, amended 37 CFR 1.321(d) to prohibit any continuation filed after the disclaimer's effective date. If you have a continuation application sitting in your docket that you might want to pursue—even a defensive one—file it before the disclaimer. The cost of filing early is the filing fee; the cost of filing late is the permanent loss of that application's subject matter.
| Scenario | Cost of pre-filing a continuation | Cost of losing broader claims | Outcome |
|---|---|---|---|
| Pharma compound (2024 disclaimer) | Filing fees plus attorney time | Substantial lost revenue | Pre-filing wins decisively |
| Semiconductor patent (2024 disclaimer) | Same fixed cost | Abandoned broader claims | Pre-filing wins decisively |
Rule 2: If no continuation is pending but you anticipate any future need for broader claims, file one before the disclaimer. The trigger here is not certainty—it is possibility. Long product lifecycles, uncertain prior art, and potential litigation all create scenarios where your current claim scope may prove insufficient. The PatentsView data on the gap between disclaimer and continuation filings (covered above) shows that applicants historically treated the continuation as a follow-up option. That option no longer exists. The pre-filed continuation is your only hedge against a future where your claims are too narrow. File it even if you are not sure you will use it; the fee is a small price for preserving optionality.
Rule 3: If you are absolutely certain your current claims are the broadest you will ever need, you may skip the continuation—but document that decision. This is the narrow exception, and it requires a written record. The decision to forgo a continuation must be made deliberately, not by default. Document the reasoning: the claim scope, the product lifecycle, the competitive landscape, and the absence of anticipated litigation. This documentation s
```
Frequently Asked Questions
What is the Federal Register citation for the proposed terminal disclaimer rule?
The NPRM was published on May 10, 2024, at 89 Fed. Reg. 40439.
What happens to a patent if a claim is finally held invalid under Sections 102 or 103 after a terminal disclaimer is filed?
Under the proposal, a patent with a terminal disclaimer becomes unenforceable upon a final invalidity finding under 102/103.
Does the new rule apply to terminal disclaimers filed for applications that were filed before the rule's effective date?
It applies to all terminal disclaimers filed on or after the effective date, regardless of the underlying application's filing date.
Are reissue applications subject to the prohibition on post-disclaimer continuations?
The only exception carved out is for reissue applications, which are not considered continuations under the rule.
What happens if you file a divisional application after a terminal disclaimer under the 2024 rule?
If you file a divisional after the disclaimer, it will be rejected as improper.
According to the IPWatchdog study, how often was a continuation filed after the terminal disclaimer in cases where a continuation was filed?
In a large majority of those continuation cases, the continuation was filed after the terminal disclaimer was filed.
Quick answers
| What is the effective date of the USPTO's final rule that amends 37 CFR 1.321(d)? | The article states that the rule's effective date is the trap, but it does not specify the exact date; it says the final rule was published in the Federal Register on that date. |
| What does the 2024 rule require any terminal disclaimer filed to overcome a non-statutory double patenting rejection to include? | The rule requires that any terminal disclaimer filed to overcome a non-statutory double patenting rejection include a provision where the applicant agrees not to file any continuation or continuation-in-part application that would extend the patent's term beyond the original patent's term. |
| What is the only exception carved out under the 2024 rule regarding post-disclaimer filings? | The only exception carved out is for reissue applications, which are not considered continuations under the rule. |
| What happens to a divisional application filed after a terminal disclaimer under the 2024 rule? | If you file a divisional after the disclaimer, it will be rejected as improper; the exception does not cover divisional applications. |
| What is the only safe strategy for practitioners under the 2024 rule according to the article? | The only safe strategy is to file the continuation before the disclaimer, even if you are not certain you will need it. |
Sources: Reddit, Reddit, arXiv, arXiv, Reddit
Also worth reading: Federal filing shakes up Disney InterDigital legal fight: Federal filing shakes up Disney · Policymakers prioritize patent quality over volume as global filing numbers continue to soar: Policymakers prioritize patent quality over · Trial lawyers use AI predictive analysis to transform patent litigation strategy: Trial lawyers use AI predictive